Abstract
Adjuvant treatment strategies in uveal melanoma require determination of prognostic factors. Patients, who received primary therapy in 1994 and 1995 at our institution, were analysed. Of 271 patients 85% and 71% were available for follow up of ⩾4 and ⩾5 years. Forty three patients (15.9%) developed metastases. Kaplan–Meier analysis revealed a 5-year progression free survival (PFS) of 79% for the whole patient cohort. Extraocular tumor growth (EOG), ciliary body involvement or a largest tumor diameter (LTD) >14 mm were associated with a significantly lower 5-year PFS of 28%, 61.4% or 67.6%. In multivariate analysis time to progression was significantly associated with ciliary body involvement and LTD, and survival was associated with ciliary body involvement. Ciliary body involvement profoundly increased the risk for metastases (hazard ratio 6.9, P<0.001) within the first 3 years. This study determined patients with ciliary body involvement to be candidates for future adjuvant therapeutic interventions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
